Education
About Us
Working with TipRanks
Follow Us
Heron Therapeutics (HRTX)
NASDAQ:HRTX
Total Valuation
Heron Therapeutics has a market cap or net worth of $321.91M. The enterprise value is ―.
Market Cap$321.91M
Enterprise Value―
Share Statistics
Heron Therapeutics has 152,563,630 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding152,563,630
Owned by Insiders5.29%
Owned by Institutions0.03%
Financial Efficiency
Heron Therapeutics’s return on equity (ROE) is 0.40 and return on invested capital (ROIC) is -7.97%.
Return on Equity (ROE)0.40
Return on Assets (ROA)-0.06
Return on Invested Capital (ROIC)-7.97%
Return on Capital Employed (ROCE)-0.08
Revenue Per Employee1.18M
Profits Per Employee-111.31K
Employee Count122
Asset Turnover0.62
Inventory Turnover0.73
Valuation Ratios
The current PE Ratio of Heron Therapeutics is -17.18. Heron Therapeutics’s PEG ratio is -0.51.
PE Ratio-17.18
PS Ratio0.00
PB Ratio-10.29
Price to Fair Value-6.93
Price to FCF-14.21
Price to Operating Cash Flow-15.36
PEG Ratio-0.51
Income Statement
In the last 12 months, Heron Therapeutics had revenue of 144.28M and earned -13.58M in profits. Earnings per share was -0.09.
Revenue144.28M
Gross Profit105.64M
Operating Income-11.53M
Pretax Income-13.58M
Net Income-13.58M
EBITDA-5.06M
Earnings Per Share (EPS)-0.09
Cash Flow
In the last 12 months, operating cash flow was -22.53M and capital expenditures -1.71M, giving a free cash flow of -24.23M billion.
Operating Cash Flow-22.53M
Free Cash Flow-24.23M
Free Cash Flow per Share-0.16
Dividends & Yields
Heron Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.59
52-Week Price Change-27.05%
50-Day Moving Average2.21
200-Day Moving Average1.90
Relative Strength Index (RSI)44.82
Average Volume (3m)1.67M
Important Dates
Heron Therapeutics upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
Heron Therapeutics as a current ratio of 2.29, with Debt / Equity ratio of -528.25%
Current Ratio2.29
Quick Ratio1.70
Debt to Market Cap0.76
Net Debt to EBITDA-30.06
Interest Coverage Ratio-1.91
Taxes
In the past 12 months, Heron Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Heron Therapeutics EV to EBITDA ratio is -76.19, with an EV/FCF ratio of -15.89.
EV to Sales2.67
EV to EBITDA-76.19
EV to Free Cash Flow-15.89
EV to Operating Cash Flow-17.10
Balance Sheet
Heron Therapeutics has $59.28M in cash and marketable securities with $177.76M in debt, giving a net cash position of $118.48M billion.
Cash & Marketable Securities$59.28M
Total Debt$177.76M
Net Cash$118.48M
Net Cash Per Share$0.78
Tangible Book Value Per Share-$0.22
Margins
Gross margin is 68.71%, with operating margin of -7.99%, and net profit margin of -9.41%.
Gross Margin68.71%
Operating Margin-7.99%
Pretax Margin-9.41%
Net Profit Margin-9.41%
EBITDA Margin-3.50%
EBIT Margin-5.23%
Analyst Forecast
The average price target for Heron Therapeutics is $6.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.33
Price Target Upside208.78% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast12.43%
EPS Growth Forecast91.67%